Alcon wins Patanol® US patent infringement lawsuit against Apotex

Alcon wins Patanol® US patent infringement lawsuit against Apotex

Patanol® is the world's leading prescription eye drop used to treat the signs and symptoms of allergic conjunctivitis
US court decision is an important milestone to defend Alcon's intellectual property rights until the Patanol patent expires in 2015
 
Basel, May 24, 2011 - Novartis announced today, that two affiliates of its Alcon Division, Alcon Laboratories, Inc. and Alcon Research, Ltd. have prevailed in a US patent infringement lawsuit filed along with Kyowa Hakko Kirin Co. Ltd. ("Kyowa") against Apotex, Inc. and Apotex Corp. (collectively, "Apotex") in the US District Court for the Southern District of Indiana.
 
Alcon's lawsuit was filed in response to Apotex's submission of an Abbreviated New Drug Application ("ANDA") to the US Food and Drug Administration ("FDA") requesting approval to manufacture and sell a generic version of Alcon's Patanol® (olopatadine hydrochloride ophthalmic solution) prior to the expiration of US patent number 5,641,805, which is jointly owned by Alcon and Kyowa. The court's decision, which is subject to appeal, would prevent Apotex from bringing its generic version of the drug to market prior to the Patanol patent expiration in 2015.
 
"We are pleased with the court's decision affirming the validity and enforceability of the Patanol patent," said Stuart Raetzman, Area President US and Vice President Global Marketing, Alcon. "Alcon invested many years and millions of dollars in the discovery and development of an ocular allergy product that would stabilize mast cells in the eye and provide long-term relief of the signs and symptoms of ocular allergies. Patanol was the result of this R&D effort and today's court decision is an important milestone to defend Alcon's intellectual property rights." 
 
Patanol, also known in many countries as Opantanol® solution, is the world's leading prescription eye drop used to treat the signs and symptoms of allergic conjunctivitis, including itching, redness, chemosis, tearing, and lid swelling. Today, the Patanol family of products account for more than three out of every four prescriptions written for ocular allergies in the US.
 
The case is referred to as Alcon Research, Ltd. et al. v. Apotex, Inc. et al., case number 1:06-cv-1642-RLY-TAB in the US District Court for the Southern District of Indiana -Indianapolis Division.
 
Disclaimer
These materials contain forward-looking statements that can be identified by terminology such as "milestone," " would," or similar expressions, or by express or implied discussions regarding any potential appeal from the District Court's ruling, or the results of any such appeal, or regarding potential future revenues from Patanol. You should not place undue reliance on these statements.  Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with Patanol to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantees as to whether an appeal might be filed from the District Court's ruling by Apotex, or as to the potential outcome of any such appeal or its timing.  Neither can there be any guarantee that Patanol will achieve any particular levels of revenue in the future. In particular, management's expectations regarding Patanol could be affected by, among other things, the company's ability to obtain or maintain patent or other proprietary intellectual property protection, including unexpected patent litigation outcomes; unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; government, industry and general public pricing pressures; competition in general; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
 
About Alcon
Building on its heritage of more than 65 years, Alcon, the global leader in eye care, is the second largest division of the Novartis Group with combined pro forma sales of more than USD 9.4 billion in 2010. Alcon has more than 22,000 employees with headquarters in Fort Worth, Texas, USA. Alcon's three businesses - Surgical, Pharmaceutical and Vision Care - meet the diverse needs of eye care professionals and patients offering the widest spectrum of eye care products with operations in 75 countries and products available in 180 markets. For more information, visit www.alcon.com.
 
About Novartis
Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, consumer health products, preventive vaccines and diagnostic tools. Novartis is the only company with leading positions in these areas. In 2010, the Group's continuing operations achieved net sales of USD 50.6 billion, while approximately USD 9.1 billion (USD 8.1 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 119,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.
 
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.
 
# # #
 
Novartis Media Relations
 
Central media line : +41 61 324 2200
Eric Althoff
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)
[email protected] Bettina Maunz
Alcon Communications
+1-404-384-0067
[email protected]

 
e-mail: [email protected]
 
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis 
For questions about the site or required registration, please contact: [email protected] .
 
Novartis Investor Relations
 
Central phone:+41 61 324 7944 
Susanne Schaffert+41 61 324 7944North America:
Pierre-Michel Bringer+41 61 324 1065Richard Jarvis+1 212 830 2433
Thomas Hungerbuehler+41 61 324 8425Jill Pozarek+1 212 830 2445
Isabella Zinck+41 61 324 7188Edwin Valeriano+1 212 830 2456
   
e-mail: [email protected] e-mail: [email protected]

Suggested Articles

An oncologist leader RBC Capital Markets interviewed expressed comfort that Trodelvy will succeed in earlier-line TNBC and in HR-positive disease.

Gilead Sciences is the latest drugmaker to settle Justice Department claims that its charity contributions were actually kickbacks.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.